Navigation Links
Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
Date:10/30/2007

p>

beginning of

the period 3,491,511 3,511,357 6,923,889 7,224,307 -

-------------------------------------------------------------------------

Cash and cash

equivalents,

end of

the period 3,326,374 3,957,086 3,326,374 3,957,086 3,326,374

-------------------------------------------------------------------------

-------------------------------------------------------------------------

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION

AND RESULTS OF OPERATIONS

This discussion and analysis should be read in conjunction with the unaudited financial statements of Oncolytics Biotech Inc. as at and for the three and nine months ended September 30, 2007 and 2006, and should also be read in conjunction with the audited financial statements and Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") contained in our annual report for the year ended December 31, 2006. The financial statements have been prepared in accordance with Canadian generally accepted accounting principles ("GAAP").

FORWARD-LOOKING STATEMENTS

The following discussion contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including our belief as to the potential of REOLYSIN(R) as a cancer therapeutic and our expectations as to the success of our research and development and manufacturing programs in 2007 and beyond, future financial position, business strategy and plans for future operations, and statements that are not historical facts, involve known and unknown risks and uncertainties, which could cause our actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the need for and availability of funds and resources to pursue research and develop
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Related biology technology :

1. The state of global biotech: An Ernst & Young perspective
2. Olympics of biotechnology has international flavor
3. Biotech officials praise focus of new venture fund
4. Getting noticed in Genetown: Wisconsin biotech on display
5. Madison biotech NimbleGen files for IPO; one of states best-funded firms
6. Wisconsin biotech firm receives $107K NIH grant
7. Biotech executive books a career flight thats closer to home
8. Manufacturing partnership will move into biotech and biomedical spaces
9. Wisconsin wont get Georgia biotech without a fight
10. The 10 biggest events shaping biotech in 2006
11. Gala Biotech among companies sold for $3.3 billion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/26/2014)... (PRWEB) October 26, 2014 The report ... by Application - Global Trends & Forecast to 2019", ... analysis and forecasting of volume consumed and value generated. ... 4,253.9 KT in 2014 to 6,701.3 KT by 2019, ... , Browse 91 market data tables and 22 figures ...
(Date:10/25/2014)... Los Angeles, California (PRWEB) October 23, 2014 ... VDRM ), a specialty pharmaceutical company devoted to ... pursuing out-licensing partnerships in 2015. , ViaDerma has ... method, which allows for rapid mass transfer of ... into the body to provide immediate localized therapy. ...
(Date:10/25/2014)... October 24, 2014 According to ... by Data Center Types (Colocation, Enterprise, Telecom), by ... (Tier 1, Tier 2, Tier 3, Tier 4) ... defines and segments the Data Center Construction Market ... forecasting of revenues. This research report also identifies ...
(Date:10/25/2014)... Va. (PRWEB) October 24, 2014 ... the nation’s leading nonprofit authority on the ... healthcare information exchange, announces its appointment of four ... Workgroup. The workgroup leaders include:, , ... ,     Erik Pupo, Specialist Leader, Deloitte Consulting ...
Breaking Biology Technology:Protective Coatings Market Poised to Reach $18,431.8 Million by 2019 - Report by MarketsandMarkets 2Protective Coatings Market Poised to Reach $18,431.8 Million by 2019 - Report by MarketsandMarkets 3Protective Coatings Market Poised to Reach $18,431.8 Million by 2019 - Report by MarketsandMarkets 4ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 2ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 3Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 2Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 3Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 4WEDI Appoints Four New Security and Privacy Workgroup Co-chairs 2
... ... Office has announced the launch of several innovative new programs to aid ... The first is aimed at entrepreneurs and offers them the opportunity ... 24 months without requiring any equity in their start-up companies. The ...
... , ROCKAWAY, N.J., Dec. 14 The ... , published by the Infusion Nurses Society ... Anthracyclines are a group of chemotherapy medications including daunorubicin, ... treatment of various types of cancer since the early 1970s.(2) ...
... ... Powder Flow Tester – helping Brookfield move from sheet metal to a plastic enclosure ... ... a US-based thermoforming company, has completed the delivery of Brookfield Engineering’s Powder Flow Tester ...
Cached Biology Technology:The Prinz Law Office Launches Innovative New Programs to Aid Cash-Strapped Entrepreneurs and Businesses 2Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 2Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 3Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 4Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 5Thermofab Helps Brookfield Engineering Move To A Compact Custom Plastic Enclosure 2
(Date:10/29/2014)... Online registration is open for the ... Scientific Meeting. SIR 2015 is the one ... trainees and related health care professionals can ... image-guided science and technologies being presented, discussed ... community in minimally invasive, image-guided medicine, SIR ...
(Date:10/29/2014)... household and industrial products are in the environment – ... of them, scientists have yet to determine whether they ... toward doing that by estimating which substances people are ... in the ACS journal Environmental Science & Technology ... the risks to human health of any given substance ...
(Date:10/29/2014)... LANSING, Mich. – As bodies decompose, their types ... the clues they provide could mean the difference ... , Michigan State University is using a more ... help Detroit death-scene investigators examine these changing populations. ... as geographical location of death, gender, race, socioeconomic ...
Breaking Biology News(10 mins):SIR 2015: Interventional radiology shapes tomorrow's medicine 2MSU partners with Detroit to investigate death scenes 2
... FL, January 13, 2014 Scientists from the Florida campus ... of drug candidates that advance the search for new treatments ... drug scaffolds, described in a recent edition of The ... act on a demonstrated therapeutic target, the kappa opioid receptor ...
... have devised a way to measure the mass of ... one millionth of a trillionth of a gram. Weighing ... components of cells, could help researchers better understand their ... technology previously developed by Scott Manalis, an MIT professor ...
... say they practice some form of yoga and/or meditation. ... these practices seems unknown or elusive to many practitioners ... during meditation practice , by Fred Travis, PhD, Director ... at Maharishi University of Management, provides an overview ...
Cached Biology News:Scientists develop promising drug candidates for pain, addiction 2Weighing particles at the attogram scale 2Weighing particles at the attogram scale 3Weighing particles at the attogram scale 4Transcendental experiences during meditation 2Transcendental experiences during meditation 3
...
... Dyad instrument is the most advanced thermal ... world-class thermal performance, the Dyad also boasts ... as point-and-click navigation via touch pad or ... easily and economically expanded to a four-bay ...
...
Kit for testing the ability of a compound to simulate lipolysis in cultured human adipocytes. Kit contains controls, buffers and reagents for detecting glycerol and non-esterified free fatty acids. A...
Biology Products: